Posted on 354
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the fourth quarter and full year of 2020. Total revenues for the full year of 2020 were $6,069.9 million, a 22 percent increase compared to the same period in 2019. The negative impact of foreign currency on total revenues year-over-year was 1 percent, or $52.0 million, inclusive of hedging activities. On a GAAP basis, diluted EPS for the full year of 2020 was $2.72, compared to $10.70 in the prior year. Full year 2020 includes impairment charges of $2,053.3 million primarily relating to the KANUMA intangible asset and a related deferred tax benefit of $377.3 million. Full year 2019 includes one-time tax benefits of $382.2 million related to intra-entity asset transfers of intellectual property. Non-GAAP diluted EPS for the full year of 2020 was $12.51, a 19 percent increase versus the prior year.
In times of political crisis, minds are moved to investigate fundamental concepts such as power and representation and legitimacy, the shorthand for the relationship between these two terms. This bearing is more pertinent than ever during a pandemic.
Our age the era of the nation state generally proffers two public arguments for political representativeness. One is the periodic vote, meant to be as universal as possible, and the other are variations on authoritarianism, usually based on a person, a family, a religion or a party being the manifestation of the nation. There is a third now quite obvious dimension, though, and this stems from the critical contingencies of the moment that which falls to technocrats and experts.
Close icon
Two crossed lines that form an X . It indicates a way to close an interaction, or dismiss a notification. A college student in Chicago, Illinois gets tested for COVID-19. Youngrae Kim/Chicago Tribune/Tribune News Service via Getty Images
Since the fall, researchers have identified worrisome coronavirus variants spreading worldwide.
To spot these mutated strains, scientists must genetically sequence samples from infected patients.
But the US sequences just 0.01% of its coronavirus cases, which Dr. Fauci says is inexcusable.
Thousands of coronavirus strains circulate all the time.
Each version of the virus is separated by a handful of tiny changes in its genome. To keep tabs on these strains, and identify which ones may be better at infecting humans or evading vaccines, researchers must genetically sequence samples of the virus.
A college student in Chicago, Illinois gets tested for COVID-19.
Youngrae Kim/Chicago Tribune/Tribune News Service via Getty Images
Since the fall, researchers have identified worrisome coronavirus variants spreading worldwide.
To spot these mutated strains, scientists must genetically sequence samples from infected patients.
But the US sequences just 0.01% of its coronavirus cases, which Dr. Fauci says is «inexcusable.»
Thousands of coronavirus strains circulate all the time.
Each version of the virus is separated by a handful of tiny changes in its genome. To keep tabs on these strains, and identify which ones may be better at infecting humans or evading vaccines, researchers must genetically sequence samples of the virus.